Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640767 | 0.81 | PDE4D (0.59) | PDE4DHCAR2DYRK1ADAOKMT2A | |
| SCHEMBL23926008 | 0.79 | PDE4D (0.57) | PDE4DHCAR2DYRK1ADAOKMT2A | |
| SCHEMBL27575758 | 0.79 | HCAR2 (0.61) | PDE4DHCAR2DAO | |
| SCHEMBL15777023 | 0.79 | PDE4D (0.57) | PDE4DHCAR2DYRK1ADAOKMT2A | |
| SCHEMBL10488455 | 0.77 | HCAR2 (0.44) | PDE4DHCAR2DAOKMT2ALMNA | |
| SCHEMBL22558031 | 0.77 | PDE4D (0.41) | PDE4DHCAR2DAOKMT2ALMNA | |
| SCHEMBL26927107 | 0.77 | HCAR2 (0.44) | PDE4DHCAR2DAOKMT2ALMNA | |
| SCHEMBL22558287 | 0.77 | HCAR2 (0.44) | PDE4DHCAR2DAOKMT2ALMNA | |
| SCHEMBL4754626 | 0.77 | PDE4D (0.66) | PDE4DDYRK1AKMT2ALMNAL3MBTL1 | |
| SCHEMBL11209524 | 0.77 | HCAR2 (0.44) | PDE4DHCAR2DAOKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122006529-A | CO under humid condition through hydrophobic regulation and control of pore environment2Preparation method of separated MOF-based mixed matrix membrane | 太原理工大学 | 2026-05-12 | — | — | CN | claimed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | claimed |
| CN-119971792-A | Metal-organic framework mixed matrix membrane and preparation method and application thereof | 天津工业大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119909545-A | Universal repair method for MOF membrane grain boundary defects, MOF membrane repaired by using method, preparation method and gas separation application thereof | 天津工业大学 | 2025-05-02 | — | — | CN | claimed |
| CN-119570491-A | Fluorine-containing etching solution | 湖北兴福电子材料股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119074956-A | Antioxidant nano-enzyme for defective metal organic frame, and preparation method and application thereof | 中国人民解放军空军军医大学 | 2024-12-06 | — | — | CN | claimed |
| CN-111040128-A | Closed water-based isocyanate curing agent with dissociable hydrophilic groups and preparation method thereof | 杭州传化精细化工有限公司 | 2020-04-21 | — | — | CN | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| EP-2161994-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-17 | — | — | EP | claimed |
| CN-101410116-A | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-15 | — | — | CN | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-20080318973-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-25 | — | — | US | claimed |
| WO-2008153902-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | WO | claimed |
| EP-1993554-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-26 | — | — | EP | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | claimed |
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | claimed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | PDE4D 1140/4885HCAR2 41/4885DYRK1A 2606/4885 |
| US-20080318973-A1 | Urotensin II receptor antagonists | UTS2R, BDKRB2, AGTR2 | PDE4D 1623/4885HCAR2 170/4885DYRK1A 2902/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | PDE4D 1140/4885HCAR2 41/4885DYRK1A 2606/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | PDE4D 616/4885HCAR2 3796/4885DYRK1A 4616/4885 |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | PDE4D 2610/4885HCAR2 2368/4885DYRK1A 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.